کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3204236 | 1587150 | 2013 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Severe Asthma: An Expanding and Mounting Clinical Challenge
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
EMTUICSATSSARPABPASABAFeNONHLBIAsthma - آسمAllergic bronchopulmonary aspergillosis - آسپرژیلوز آلرژیک برونکوپلاستیLong-acting β2-agonist - آگونیست β2 طولانی مدتShort-acting β2-agonist - آگونیست β2 کوتاه مدتAmerican Thoracic Society - انجمن قلب آمریکاImmunomodulators - ایمونومولاتورSevere Asthma Research Program - برنامه تحقیقاتی شدید آسمBronchodilators - برنشودهاFraction of exhaled nitric oxide - جزء اکسید نیتریک اکساسیون شدهWorld Health Organization - سازمان بهداشت جهانیLABA - سودanti-IgE - ضد IgE درGlobal Initiative for Asthma - طرح جهانی برای آسمNational Heart, Lung, and Blood Institute - قلب ملی، ریه و موسسه خونWHO - کهCorticosteroids - کورتیکواستروئیدهاInhaled corticosteroid - کورتیکواستروئیدهای استنشاقیGINA - گینا
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Severe Asthma: An Expanding and Mounting Clinical Challenge Severe Asthma: An Expanding and Mounting Clinical Challenge](/preview/png/3204236.png)
چکیده انگلیسی
Although all patients with asthma have variable airflow obstruction, airway inflammation, and bronchial hyperresponsiveness, some have disease that is severe in many aspects: persistent airflow obstruction, ongoing symptoms, increased frequency of exacerbations, and, most importantly, a diminished response to medications. A number of definitions have emerged to characterize the clinical features of severe asthma, but a central feature of this phenotype is the need for high doses of medications, especially corticosteroids, in attempts to achieve disease control. The prevalence of severe asthma is also undergoing reevaluation from the usual estimate of 10% to larger numbers on the basis of medication needs and the lack of disease control achieved. At present, the underlying mechanisms of severe asthma are not established but likely reflect a heterogeneous pattern, rather than a single unifying process. Guideline-directed treatment for severe asthma has limits with usual approaches centered on high doses of inhaled corticosteroids, long-acting β-agonists, and trials with omalizumab, the monoclonal antibody to IgE. With the development of approaches to recognize asthma phenotypes with distinct pathogenesis and hence unique therapeutic targets, it is hoped that a personalized strategy in treatment directed toward disease-specific features will improve outcomes for this high-risk, severely affected population of patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal of Allergy and Clinical Immunology: In Practice - Volume 1, Issue 2, March 2013, Pages 110-121
Journal: The Journal of Allergy and Clinical Immunology: In Practice - Volume 1, Issue 2, March 2013, Pages 110-121
نویسندگان
Matthew C. MD, William W. MD,